A severe case of haemodynamic instability during anidulafungin administration

被引:28
|
作者
Fink, M. [1 ,2 ]
Zerlauth, U. [2 ]
Kaulfersch, C. [3 ]
Rab, A. [3 ]
Alberer, D. [3 ]
Preiss, P. [1 ]
Sternad-Klobschauer, K. [4 ]
Habernig, E. [4 ]
Wandschneider, W. [1 ]
Grimm, G. [3 ]
机构
[1] Klinikum Klagenfurt Worthersee, Dept Cardiothorac & Vasc Surg, Klagenfurt, Austria
[2] Klinikum Klagenfurt Worthersee, Dept Hosp Epidemiol & Infect Control, Klagenfurt, Austria
[3] Klinikum Klagenfurt Worthersee, Dept Internal Med, Klagenfurt, Austria
[4] Klinikum Klagenfurt Worthersee, Dept Hosp Pharm, Klagenfurt, Austria
关键词
adverse event; anidulafungin; drug-related; intravenous infusions;
D O I
10.1111/jcpt.12046
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
What is known and objective Anidulafugin is an echinocandin used for the treatment of candida infections in non-neutropenic adults. Echinocandins show few drugdrug interactions and are usually well tolerated. We report a case of acute hypotension, bradycardia and haemodynamic instability with consecutive cardiopulmonary resuscitation during anidulafungin administration. Case summary A 41-year-old man ICU patient received anidulafungin for a suspected Candida glabrata infection. During the first administration of the drug, he developed acute haemodynamic instability with hypotension and bradycardia. The infusion was discontinued immediately and cardiopulmonary resuscitation was performed successfully. The patient regained haemodynamic stability. What is new and conclusion To the authors' knowledge, this is the first report of a life-threatening adverse event due to haemodynamic instability during anidulafungin administration. Cardiac toxicity associated with echinocandins has been described. Further studies seem to be mandatory to investigate this potential risk.
引用
收藏
页码:241 / 242
页数:2
相关论文
共 50 条